Adenosine A2A Prodrugs – Phosphorylated A2A receptor agonist prodrugs as anti-inflammatory agents with improved tolerance
A2A agonists are well known for their anti-inflammatory
action. A new class of compounds is presented that allows systemic and local application with reduced side effects due to activation of the prodrug at the site of inflammation. The invention discloses phosphorylated A2A receptor agonists and covers medicaments containing such compounds. It further discloses a method for identification of phosphorylated A2A receptor agonists. The disclosed compounds are applicable for the treatment of acute and chronic inflammation. Phosphorylated A2A receptor agonists can be considered as prodrugs, which are activated by dephosphorylation. The compounds are hydrolysed specifically by ecto-5’- nucleotidase (CD73), which is represented on the outer surface of endothelial cells of large and small arteries as well as on immune cells such as macrophages and Tlymphocytes. CD73 is also upregulated on the surfaces of inflamed tissues. Upregulation of CD73 has also been demonstrated for arteriosclerotic plaques. Therefore, activation of the prodrug directly at the site of inflammation reduced side effects can be expected.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 0
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Researchers show an old law still holds for quirky quantum materials
This surprising result is important for understanding unconventional superconductors and other materials where electrons band together to act collectively. Long before researchers discovered the electron and its role in generating…
Straining memory leads to new computing possibilities
Researchers develop hybrid phase-change memristors that offer fast, low-power, and high-density computing memory.# By strategically straining materials that are as thin as a single layer of atoms, University of Rochester scientists have…
A patch of protection against Zika virus
A simple-to-apply, needle-free vaccine patch is being developed to protect people from the potentially deadly mosquito-borne Zika virus. A prototype using The University of Queensland-developed and Vaxxas-commercialised high-density microarray patch…
